AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by BTIG Research in a research report issued on Wednesday, September 23rd, Benzinga reports. They presently have a $8.00 target price on the stock. BTIG Research’s price target would indicate a potential upside of 205.34% from the company’s current price.

ACIU has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

AC Immune Stock Performance

Shares of ACIU traded up $0.02 during midday trading on Wednesday, reaching $2.62. 199,644 shares of the stock were exchanged, compared to its average volume of 273,567. AC Immune has a twelve month low of $2.10 and a twelve month high of $4.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.93 and a quick ratio of 1.02. The company has a market capitalization of $266.64 million, a price-to-earnings ratio of -4.85 and a beta of 1.60. The business’s 50-day moving average price is $2.58 and its 200 day moving average price is $2.67.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $18.67 million during the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. On average, sell-side analysts expect that AC Immune will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AXQ Capital LP acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $25,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after buying an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after buying an additional 176,701 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.